Eledon Pharmaceuticals, Inc. — Director's Dealing 2017

May 12, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Novus Therapeutics, Inc. (NVUS)
CIK: 0001404281
Period of Report: 2017-05-10

Reporting Person: OCAMPO CHRISTINE (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-10	Common Stock	P	10010	$9.99	Acquired	21590	Direct

Footnotes

F1: All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017.